Comparative study of long-term effects of atorvastatin and rosuvastatin on fasting glucose and hemoglobin A1c in patients with cardiovascular diseases

Authors

  • Nahida Srabović Department of Biochemistry, Faculty of Pharmacy, University of Tuzla, Tuzla, Bosnia and Herzegovina https://orcid.org/0009-0006-5893-2742
  • Monika Rustemović Čorbić Department of SEE Region, Bosnalijek d.d., Sarajevo, Bosnia and Herzegovina https://orcid.org/0000-0002-6230-7417
  • Esmeralda Dautović Department of Biochemistry, Faculty of Pharmacy, University of Tuzla, Tuzla, Bosnia and Herzegovina https://orcid.org/0000-0002-1250-6581
  • Aida Smajlović Department of Biochemistry, Faculty of Pharmacy, University of Tuzla, Tuzla, Bosnia and Herzegovina https://orcid.org/0000-0002-1057-8493
  • Adaleta Softić Department of Biochemistry, Faculty of Pharmacy, University of Tuzla, Tuzla, Bosnia and Herzegovina
  • Anida Delimehić Department of Family Medicine, Public Health Center Gračanica, Bosnia and Herzegovina https://orcid.org/0009-0001-1804-2159
  • Jasmina Grapkić Aličić Department of Family Medicine, Public Health Center Gračanica, Bosnia and Herzegovina
  • Damir Terzić Department of Family Medicine, Public Health Center Gračanica, Bosnia and Herzegovina
  • Emina Hodžić Department of Family Medicine, Public Health Center Gračanica, Bosnia and Herzegovina
  • Arnela Šakušić Mujić Department of Family Medicine, Public Health Center Gračanica, Bosnia and Herzegovina
  • Ezaneta Merdanović Department of Family Medicine, Public Health Center Gračanica, Bosnia and Herzegovina
  • Zerina Sakić Department of Family Medicine, Public Health Center Banovići, Bosnia and Herzegovina
  • Eldina Žunić Department of Family Medicine, Public Health Center Banovići, Bosnia and Herzegovina
  • Mehmed Salkić Department of Family Medicine, Public Health Center Banovići, Bosnia and Herzegovina https://orcid.org/0000-0002-2403-4892
  • Aida Ždralić Department of Family Medicine, Public Health Center Čelić, Bosnia and Herzegovina

DOI:

https://doi.org/10.17532/jhsci.2023.2146

Keywords:

Cardiovascular disease, fasting glucose, hemoglobin A1c, statins

Abstract

Introduction: Statins are lipid lowering medications, used for the prevention of cardiovascular diseases (CVD), but have shown to increase the risk of Type 2 diabetes mellitus. The aim of this study was to investigate the effects of high-potency statins, atorvastatin, and rosuvastatin on fasting glucose (FG) and hemoglobin A1c (HbA1c) in CVD patients.

Methods: The case–control study included 123 patients from Tuzla Canton, Bosnia, and Herzegovina, with a diagnosis of CVD, treated in three health centers: Public Health Center Gračanica, Banovići, and Čelić. Of total patients, 84 were statin users (39 atorvastatin users and 45 rosuvastatin users) and 39 were not. Demographic data, diagnosis, and data of the therapy were taken from the medical records, as well as data of the FG and HbA1c, measured before or within 3 months of the statin therapy introduction. For the same patients, FG and HbA1c were also measured at least 3 months after the introduction of therapy.

Results: Obtained results have shown a significant increase of FG in CVD patients on statin therapy in relation to control (p = 0.034). Comparing the diabetogenic effects of atrovastatin and rosuvastatin, it was found that the HbA1c in patients on atorvastatin therapy was significantly higher comparing to those on rosuvastatain therapy (p = 0.028). The FG was significantly increased (p = 0.027) after atrovastatin therapy. Similar results were obtained in diabetogenic CVD patients, where HbA1c on atorvastatin therapy was significantly higher comparing to HbA1c in those on rosuvastatain therapy (p = 0.039). A significant correlation was found between the increase in FG and HbA1c with the duration of atorvastatin therapy (p = 0.001 and p = 0.033), and between the increase in HbA1c and the duration of rosuvastatin therapy (p = 0.001).

Conclusion: Long-term therapy with high-potency statins, atorvastatin, and rosuvastatin, may increase levels of FG and HbA1c in patients with CVD, where atorvastatin shows more significant effects.


Downloads

Download data is not yet available.

Downloads

Published

30.12.2023

Issue

Section

Research articles

Categories

How to Cite

1.
Comparative study of long-term effects of atorvastatin and rosuvastatin on fasting glucose and hemoglobin A1c in patients with cardiovascular diseases. JHSCI [Internet]. 2023 Dec. 30 [cited 2024 Nov. 10];13(3):148-53. Available from: https://www.jhsci.ba/ojs/index.php/jhsci/article/view/2146